Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Joseph Witztum
University of California, San Diego, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Isis Pharmaceuticals
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Dr. Witztum holds publicly acquired stock in Isis valuing (b)(4). In addition, he receives compensation from Isis ((b)(4) annually) via a consulting agreement. Dr. Witztum works at Isis two days a week providing consultation on issues related to the clinical application of antisense drugs to treat lipid disorders.
AIBP and Endothelial Function
Maintaining normal function of endothelial cells, which cover the surface of the vascular wall, is important for prevention and reversal of atherosclerosis and cardiovascular disease, the major cause of mortality and morbidity in the United States. We have discovered that apoA-I binding protein (AIBP) helps remove cholesterol from endothelial cells and restrict their inflammatory activation. This project will test the hypothesis that raisin AIBP levels will diminish endothelial dysfunction during development of atherosclerosis, the approach that may results in a new therapy for cardiovascular disease.
Filed on June 10, 2015.
Tell us what you know about Joseph Witztum's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Joseph Witztum”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Joseph Witztum | University of California, San Diego | Conflict of Interest | Isis Pharmaceuticals | $150,000 - $199,999 |
| Joseph Witztum | University of California, San Diego | Conflict of Interest | Isis Pharmaceuticals | $10,000 - $19,999 |
| Joseph Witztum | University of California, San Diego | Conflict of Interest | Isis Pharmaceuticals | $150,000 - $199,999 |
| Joseph Witztum | La Jolla Inst for Allergy & Immunolgy | Conflict of Interest | Isis Pharmaceuticals | $150,000 - $199,999 |
| Joseph Witztum | La Jolla Inst for Allergy & Immunolgy | Conflict of Interest | Isis Pharmaceuticals | $10,000 - $19,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.